Claims

1. Use of hMG (human menopausal gonadotropin) in the manufacture of a pharmaceutical composition for reducing aneuploidy rate in blastocyst(s) or preventing aneuploidy in blastocyst(s) in a patient,

wherein a dose of 75 to 300 IU hMG per day is to be administered to the patient from day 1 to at least day 5 of stimulation, and

wherein the patient has been identified as having a serum antimullerian hormone (AMH) level $\geq 5.2 \pm 0.5$ ng/ml and an antral follicle count (AFC) ≥ 10 in both ovaries combined prior to stimulation.

2. The use according to claim 1, wherein hCG is to be further administered to trigger ovulation.

3. The use according to any one of the preceding claims, wherein the hMG is highly purified menotropin (HPhMG).

4. The use according to any one of the preceding claims, wherein a dose of 75 to 200 IU HP-hMG per day is to be administered to the patient from day 1 to at least day 5 of stimulation.

5. The use according to any one of the preceding claims, wherein a dose of 150 IU HP-hMG per day is to be administered to the patient from day 1 to at least day 5 of stimulation.

6. The use according to any one of the preceding claims, wherein a GnRH antagonist is to be further administered on day 6 of stimulation.